In this study, we assessed the antitumor activity of sorafenib in the control of ovarian cancer cell proliferation, mobility, and radiosensitivity in vitro using the TGF-β1-enhanced ovarian cancer cell EMT model. Here, TGFB1 is linked to ovarian cancer.